FDA Adverse Event Injury Summary report: N

INFUSE BONE GRAFT

MDR report key: 3052130 · Received April 11, 2013

Report

Report Number
1030489-2013-00992
Event Type
Injury
Date Received
April 11, 2013
Report Date
July 3, 2018
Manufacturer
MEDTRONIC SOFAMOR DANEK USA, INC
Product Code
NEK
PMA / PMN Number
P000058
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
ATTORNEY

Narratives

Additional Manufacturer Narrative · 1

(B)(4): NEITHER THE DEVICE NOR FILMS OF APPLICABLE IMAGING STUDIES WERE RETURNED TO THE MANUFACTURER FOR EVALUATION. THEREFORE, WE ARE UNABLE TO DETERMINE THE DEFINITIVE CAUSE OF THE REPORTED EVENT. PRODUCTS FROM MULTIPLE MANUFACTURERS WERE IMPLANTED DURING THE PROCEDURE. ALTHOUGH IT IS UNKNOWN IF ANY OF THE DEVICES CONTRIBUTED TO THE REPORTED EVENT, WE ARE FILING THIS MDR FOR NOTIFICATION PURPOSES.

Additional Manufacturer Narrative · 1

IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE PATIENT SUSTAINED UNSPECIFIED INJURIES FOLLOWING THE USE OF RHBMP-2/ACS IN AN UNSPECIFIED SPINAL FUSION SURGERY. NO ADDITIONAL INFORMATION WAS REPORTED.

Description of Event or Problem · 1

IT WAS REPORTED THAT ON: (B)(6) 2012: THE PATIENT PRESENTED WITH THE FOLLOWING PRE-OP DIAGNOSIS: L4-5 HIGH GRADE STENOSIS AND CENTRAL DISC PROTRUSION. THE PATIENT UNDERWENT THE FOLLOWING PROCEDURES: BILATERAL L4 DECOMPRESSION, L4-5 DISCECTOMY, PEDICLE SCREW FIXATION, L4-5 LATERAL MASS FUSION, REMOVAL OF OLD HARDWARE, L5-S1 LEVEL. AS PER THE OPERATIVE NOTES, ¿LOCAL AUTOLOGOUS BONE WITH MORSELIZED DENUDED SOFT TISSUE WAS USED AS A FILLING, BMP (BONE MORPHOGENIC PROTEIN) - SOAKED SPONGES WERE LAID OVER LATERAL MASS, TRANSVERSE PROCESSES OF L4-5 BILATERALLY.¿ NO INTRA-OPERATIVE COMPLICATIONS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
155426 INFUSE BONE GRAFT FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET NEK MEDTRONIC SOFAMOR DANEK USA, INC M111104AA2

Patients

Seq Age Sex Outcome Treatment
1